Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan

References

• ValensteinMGanoczyDMcCarthyJFMyra KimHLeeTABlowFCAntipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective reviewJ Clin Psychiatry2006671542155017107245
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med200532116375765
   PubMed Web of Science ®Google Scholar
• YamadaKWatanabeKNemotoNPrediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up studyPsychiatry Res2006141616916318875
   PubMed Web of Science ®Google Scholar
• CooperCBebbingtonPKingMWhy people do not take their psychotropic drugs as prescribed: results of the 2000 National Psychiatric Morbidity SurveyActa Psychiatr Scand2007116475317559600
   PubMed Web of Science ®Google Scholar
• NasrallahHATargumSDTandonRMcCombsJSRossRDefining and measuring clinical effectiveness in the treatment of schizophreniaPsychiatr Serv20055627328215746501
   PubMed Web of Science ®Google Scholar
• KaneJCanasFKramerMTreatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trialSchizophr Res20079014716117092691
   PubMed Web of Science ®Google Scholar
• EreshefskyLMascarenasCAComparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmaco-dynamicsJ Clin Psychiatry2003641823
   PubMed Web of Science ®Google Scholar
• VermeirMBoomSNaessensITalluriKEerdekensMHargarterLAbsorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjectsEur Neuropsychopharmacol200515S648S649
   Web of Science ®Google Scholar
• MarderSRKramerMFordLEfficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyBiol Psychiatry2007621363137017601495
   PubMed Web of Science ®Google Scholar
• MeltzerHYBoboWVNuamahIFEfficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo-controlled studiesJ Clin Psychiatry20086981782918466043
   PubMed Web of Science ®Google Scholar
• ZhangHLiHLiuYSafety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled studyNeuropsychiatr Dis Treat201612697726811679
   PubMed Web of Science ®Google Scholar
• KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull1987132612763616518
   PubMed Web of Science ®Google Scholar
• MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trialsJ Clin Psychiatry1997585385469448657
   PubMed Web of Science ®Google Scholar
• EndicottJSpitzerRLFleissJLCohenJThe global assessment scale. A procedure for measuring overall severity of psychiatric disturbanceArch Gen Psychiatry197633766771938196
   PubMed Web of Science ®Google Scholar
• GuyWECDEU Assessment Manual for PsychopharmacologyRockville, MDU.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs1976
   Google Scholar
• GagnonDDAdriaenssenINasrallahHMorosiniPLReliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with stable schizophreniaInt J Neuropsychopharmacol20069S288
   Web of Science ®Google Scholar
• PatrickDAdriaenssenIMorosiniPLRothmanMReliability, validity and sensitivity to change of the Personal and Social Performance scale in patients with acute schizophreniaInt J Neuropsychopharmacol20069S287S288
   Web of Science ®Google Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV social and occupational social functioning assessment scale (SOFAS) to assess routine social functioningActa Psychiatr Scand200010132332910782554
   PubMed Web of Science ®Google Scholar
• ChouinardGMargoleseHCManual for the Extrapyramidal Symptom Rating Scale (ESRS)Schizophr Res20057624726515949657
   PubMed Web of Science ®Google Scholar
• LambertENaberDCurrent issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of lifeCNS Drugs20041851715461312
   PubMed Web of Science ®Google Scholar
• CanusoCMBossieCAAmatniekJTurkozIPandinaGCornblattBPaliperidone extended-release tablets in patients with recently diagnosed schizophreniaEarly Interv Psychiatry20104647820199482
   PubMed Web of Science ®Google Scholar
• ChiuHJChouPHLohel-WChanges in the prescription pattern of antipsychotics for schizophrenic outpatients after the implementation of a global budgeting programJ Chin Med Assoc20147732533224863739
   PubMed Web of Science ®Google Scholar
• KramerMSimpsonGMaciulisVOne-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophreniaCNS Spectr20101550651420703197
   PubMed Web of Science ®Google Scholar
• CaseyDEMetabolic issues and cardiovascular disease in patients with psychiatric disordersAm J Med2005118S15S22
   PubMedGoogle Scholar
• American Diabetes AssociationAmerican Psychiatric AssociationAmerican Association of Clinical EndocrinologistsNorth American Association for the Study of ObesityConsensus development conference on antipsychotic drugs and obesity and diabetesJ Clin Psychiatry20046526727215003083
   PubMed Web of Science ®Google Scholar
• KramerMSimpsonGMaciulisVPaliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol20072761417224706
   PubMed Web of Science ®Google Scholar
• ZhangLLiJZhaoYSuYSiTCritical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature reviewNeuropsychiatr Dis Treat20161211313126811684
   PubMed Web of Science ®Google Scholar
• ZhangHLiHLiuYSafety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled studyNeuropsychiatr Dis Treat201612697726811679
   PubMed Web of Science ®Google Scholar